title: Cangrelor.
abstract: Each month, subscribers toThe Formulary Monograph Servicereceive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly withThe Formulary Monograph Service.Through the cooperation ofThe Formulary, Hospital Pharmacypublishes selected reviews in this column. For more information aboutThe Formulary Monograph Service, callThe Formularyat 800-322-4349. The November 2015 monograph topics are evolocumab, dichlorphenamide, necitumumab, cobimetinib, and reslizumab. The Safety MUE is on alirocumab and evolocumab.
authors.affiliation: Director, Drug Information Center , and Professor of Pharmacy Practice, College of Pharmacy, Washington State University Spokane.
authors.forename: Danial E
authors.initials: DE
authors.lastname: Baker
authors.affiliation: Drug Information Resident, College of Pharmacy, Washington State University Spokane . The authors indicate no relationships that could be perceived as a conflict of interest.
authors.forename: Kyle T
authors.initials: KT
authors.lastname: Ingram